Ecological Momentary Mental Assessment (EMMA)

February 4, 2021 updated by: University Hospital, Montpellier

Development of an Algorithm and a Smartphone Application for the Evaluation and Prediction of Suicidal Risk

Suicide is a major health problem that causes annually a million death worldwide. Suicide and suicide attempts are preventable.

A history of self-injuries or suicidal attempts are known to be the most important risk factor for death by suicide. Suicidal ideation is also strongly correlated with suicide attempts.

The development of Smartphones applications offers new possibilities for data collection and transmission.

Moreover, the online help function, when a suicidal crisis occurs, is the most effective strategy for prevention of suicidal behavior.

Specific technologies have been developed to analyse behaviors and experiences of patients in a natural environment, in real life.

That is the goal of Ecological Momentary Assessment.

The aim of the study is to develop an algorithm to assess and predict the risk of suicidal event occurrence, in order to detect as soon as possible the signs of suicidal crisis.

EMMA will be the first application in French, meeting the recommendations for health applications, developed by experts on suicidal behavior and in collaboration with patients which aims to predict suicidal risk.

A subsequent study, conducted on a larger population, should allow to validate the predictive algorithm of EMMA.

Long-term goal is to improve the care of patients at risk for suicidal behavior.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

100 patients having recently attempted suicide or having suicidal ideation will be recruited. They will be asked to use the application EMMA during 6 months and will be followed up during this period.

An optional qualitative study conducted on 25 patients will allow to evaluate more finely their subjective experience of the use of the application.

Initial visit (inclusion) : clinical, biological and neuropsychological assessment and installation of the application EMMA.

First visit (1st month) and second visit (3rd month) : clinical assessment

Last visit (6th month) : clinical, biological and neuropsychological assessment and optional qualitative interview.

Study Type

Interventional

Enrollment (Actual)

97

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Montpellier, France, 34000
        • MontpellierUniversity Hopital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Recent suicidal attempt (< 8 days) or suicidal ideation score ≥ 2 (IDSC-30 scale)
  • More than 18 years old
  • Able to understand nature, aims, and methodology oh the study
  • To own a smartphone

Exclusion Criteria:

  • Refusal to participate
  • Patient on protective measures (guardianship or trusteeship)
  • Deprived of liberty subject (administrative decision)
  • Subject in exclusion period for another protocol
  • Not affiliated to a social security agency
  • Unable to understand and/or answer a questionnaire

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group using the application EMMA
Patients with personal history of suicide attempt or with suicidal ideation, will use the application during 6 months. Assessment of the predictive value of the algorithm for suicidal risk, acceptbability and satisfaction
Emma proposes four types of assessments during 6 months:1) 5 times a day during 3 days, every month (5 minutes): patients can assess their emotions, their thoughts, their behavior and their occurrence context. 2) Weekly (7 minutes): consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends, and their quality of life.3) Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.4) Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help. They can contact a relative or call the psychiatric emergency service directly by clicking on a button.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Occurrence of a suicidal event during the follow-up
Time Frame: At 6 months
Occurrence of a suicidal event will be checked by the Columbia Suicide Severity Rating Scale (C-SSRS) questionnaire and medical records at the end of study.
At 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of the frequency of connection of the patient to the EMMA application
Time Frame: At 1 month
The use is automatically measured by the application with the connection frequency
At 1 month
Evaluation of the frequency of connection of the patient to the EMMA application
Time Frame: At 2 months
The use is automatically measured by the application with the connection frequency
At 2 months
Evaluation of the frequency of connection of the patient to the EMMA application
Time Frame: At 3 months
The use is automatically measured by the application with the connection frequency
At 3 months
Evaluation of the frequency of connection of the patient to the EMMA application
Time Frame: At 4 months
The use is automatically measured by the application with the connection frequency
At 4 months
Evaluation of the frequency of connection of the patient to the EMMA application
Time Frame: At 5 months
The use is automatically measured by the application with the connection frequency
At 5 months
Evaluation of the frequency of connection of the patient to the EMMA application
Time Frame: At 6 months
The use is automatically measured by the application with the connection frequency
At 6 months
Acceptability of EMMA assessed by the Smartphone application
Time Frame: At 1 month
Questionnaire passed with the application (Likert scales)
At 1 month
Acceptability of EMMA assessed by the Smartphone application
Time Frame: At 2 months
Questionnaire passed with the application (Likert scales)
At 2 months
Acceptability of EMMA assessed by the Smartphone application
Time Frame: At 3 months
Questionnaire passed with the application (Likert scales)
At 3 months
Acceptability of EMMA assessed by the Smartphone application
Time Frame: At 4 months
Questionnaire passed with the application (Likert scales)
At 4 months
Acceptability of EMMA assessed by the Smartphone application
Time Frame: At 5 months
Questionnaire passed with the application (Likert scales)
At 5 months
Acceptability of EMMA assessed by the Smartphone application
Time Frame: At 6 months
Questionnaire passed with the application (Likert scales)
At 6 months
Acceptability of EMMA assessed by the self assessment questionnaire Mobile Application Rating Scale (MARS)
Time Frame: At 6 months
At 6 months
Acceptability of EMMA assessed by a qualitative interview
Time Frame: At 6 months
The qualitative interview is optional
At 6 months
Satisfaction of EMMA assessed by the Smartphone application
Time Frame: At 1 month
Questionnaire passed with the application (Likert scales)
At 1 month
Satisfaction of EMMA assessed by the Smartphone application
Time Frame: At 2 months
Questionnaire passed with the application (Likert scales)
At 2 months
Satisfaction of EMMA assessed by the Smartphone application
Time Frame: At 3 months
Questionnaire passed with the application (Likert scales)
At 3 months
Satisfaction of EMMA assessed by the Smartphone application
Time Frame: At 4 months
Questionnaire passed with the application (Likert scales)
At 4 months
Satisfaction of EMMA assessed by the Smartphone application
Time Frame: At 5 months
Questionnaire passed with the application (Likert scales)
At 5 months
Satisfaction of EMMA assessed by the Smartphone application
Time Frame: At 6 months
Questionnaire passed with the application (Likert scales)
At 6 months
Satisfaction of EMMA assessed by the satisfaction questionnaire
Time Frame: At 6 months
At 6 months
Satisfaction of EMMA assessed by a qualitative interview
Time Frame: At 6 months
The qualitative interview is optional
At 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 31, 2018

Primary Completion (Actual)

June 26, 2020

Study Completion (Actual)

June 26, 2020

Study Registration Dates

First Submitted

December 14, 2017

First Submitted That Met QC Criteria

January 18, 2018

First Posted (Actual)

January 25, 2018

Study Record Updates

Last Update Posted (Actual)

February 5, 2021

Last Update Submitted That Met QC Criteria

February 4, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 9867
  • 2017-A22108-45 (Other Identifier: Agence Nationale de Securité des Médicaments et produist de santé)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Person at Risk of Suicide

Clinical Trials on Application EMMA

Subscribe